Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis.
about
The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRαTyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia.The platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) are major players in oncogenesis, drug resistance, and attractive oncologic targets in cancer.Myeloid Neoplasms with t(5;12) and ETV6-ACSL6 Gene Fusion, Potential Mimickers of Myeloid Neoplasm with PDGFRB Rearrangement: Case Report with Imatinib Therapy and Review of the Literature.MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia.PDGFRᵝ-Rearranged Myeloid Neoplasm with Marked Eosinophilia in a 37-Year-Old Man; And a Literature Review.Quantification of PDGFRA alternative transcripts improves the screening for X-PDGFRA fusions by reverse transcriptase-polymerase chain reaction.Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.Platelet-derived growth factors and their receptors in normal and malignant hematopoiesisMyeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1.F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA protein stability via SHP-2 and SRC: a novel mode of kinase inhibitor resistance.Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase.Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.Enhanced expression and phosphorylation of the MET oncoprotein by glioma-specific PTPRZ1-MET fusions.Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia.Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib.Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms.The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.A new four-way variant t(5;17;15;20)(q33;q12;q22;q11.2) in acute promyelocytic leukemia.ATF7IP as a novel PDGFRB fusion partner in acute lymphoblastic leukaemia in children.Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement.A case of chronic eosinophilic leukemia with secondary transformation to acute myeloid leukemia.Targeted next-generation sequencing detects point mutations, insertions, deletions and balanced chromosomal rearrangements as well as identifies novel leukemia-specific fusion genes in a single procedureLeriche’s syndrome and Löffler endocarditis in a 30-year-old patient presenting with hypereosinophilic syndromePATRI, a Genomics Data Integration Tool for Biomarker Discovery
P2860
Q28535951-E902C036-A2F1-42D5-BDCB-17A88E432A60Q37919976-26CD31F5-558F-49E1-9390-26ADF3F087A4Q38131481-6385821D-9858-42C1-B68B-5D1459D5EBD0Q38832520-0228A28A-2898-42FF-994B-7D3D9A934637Q38982112-65F8F5C0-8A59-4C25-93AD-A56E6C7B55E8Q39004166-CB6CA0E8-FBF0-4747-9845-5632D9474D97Q39139762-2B1772A7-F22E-4688-9FDE-9FCD500837A6Q39682810-36104F07-AF05-4CAF-AC26-69F1D624BAC6Q40115606-F9174EF0-CF71-4509-942C-8A99F2B4F2C2Q40822125-8E1C7475-FB28-4FFE-B46E-C83E2645C5DEQ42126072-7793C30E-35B1-4C9B-90F1-E55F3AFEB6F2Q42793025-47B66F7B-6378-40C0-AB22-FDE4CA671D6CQ42829472-5EB02A28-6EF4-456E-9209-6BF5F93E3D63Q44652111-70A4B1DD-F27F-476C-888A-5819BDD1390AQ46476524-C784E454-BF53-4D02-BE83-021DDE33497DQ48196960-1A5E71AC-3203-49A6-825D-B4CFB4415718Q49536138-2749450D-B7E3-43FB-99D9-142FADCD2E71Q53289961-1DF3E9B1-938F-494C-9C70-5157AF83EF01Q53350377-10654DDA-311F-45D3-B1F3-718921EBC576Q54234141-2F08FE64-19D4-45FA-B9FD-702BFD5CBC3BQ54348376-D2C73343-59CC-4163-9EC9-E055D473C75AQ54368721-EF673B60-961A-445F-A168-B8AA11AA77B7Q54510843-F0F47064-862B-495F-BE90-0FC4F3101734Q55253253-B24D0537-7D6D-45C5-89F0-22C614A5623EQ57740688-45E63B6B-C1B5-4B01-A73D-CC42AE2F2B6AQ58023790-7CE85225-59E2-408F-B1C3-27FB9136A10FQ58883545-E2F72263-4CAF-4208-80F2-379A30D94180
P2860
Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Screening for diverse PDGFRA o ...... erase chain reaction analysis.
@ast
Screening for diverse PDGFRA o ...... erase chain reaction analysis.
@en
type
label
Screening for diverse PDGFRA o ...... erase chain reaction analysis.
@ast
Screening for diverse PDGFRA o ...... erase chain reaction analysis.
@en
prefLabel
Screening for diverse PDGFRA o ...... erase chain reaction analysis.
@ast
Screening for diverse PDGFRA o ...... erase chain reaction analysis.
@en
P2093
P2860
P50
P1433
P1476
Screening for diverse PDGFRA o ...... erase chain reaction analysis.
@en
P2093
Andreas Reiter
Christoph Walz
Darko Gosenca
Francesco Del Valle
Jelena Reinhard
Joannah Score
Jürgen Mix
Martin C Müller
Nicholas C P Cross
Philipp Erben
P2860
P304
P356
10.3324/HAEMATOL.2009.016345
P577
2010-01-27T00:00:00Z